COPD patients express hardships in new GSK study
RESEARCH TRIANGLE PARK, N.C. Patients living with chronic obstructive pulmonary disease said the illness prevented them from living life to its fullest, according to research conducted by drug maker GlaxoSmithKline.
GSK, which makes the COPD and asthma treatment Advair Diskus (fluticasone propionate and salmeterol inhalation powder), marked World COPD Day on Wednesday by announcing results of its research, which show patients as feeling a loss of energy, control, independence and their old selves. People reported becoming increasingly limited in their daily activities and relying on the Internet to find information and interact with people who share their experiences.
COPD affects around 12 million people in the United States who typically have emphysema, chronic bronchitis or both.
Takeda launches GetToKnowGERD.com
NEW YORK — Drug maker Takeda Pharmaceuticals is launching a campaign to raise awareness of gastroesophageal reflux disease, the company said Tuesday.
Takeda created the website GetToKnowGERD.com to coincide with GERD Awareness Week, which takes place from Nov. 21 to 27. The company also is using the occasion to promote the GERD drug Dexilant (dexlansoprazole).
GERD is an often chronic condition characterized by frequent heartburn that affects nearly 19 million Americans, but according to an Omnibus telephone poll of 1,000 U.S. adults conducted in October, around 80% of people are not aware of how common it is.
Labopharm reviewing notification of Actavis’ approval application for generic Oletpro
LAVAL, Quebec — Generic drug maker Actavis has filed for approval of a generic version of an antidepressant made by Canada’s Labopharm, Labopharm said.
The drug maker said it received a notification stating that Actavis had applied to the Food and Drug Administration for approval of a generic version of Oletpro (trazodone hydrochloride) extended-release tablets in the 150-mg and 300-mg strengths.
Actavis’ application contained a Paragraph IV certification, a legal challenge to a Labopharm patent covering the drug, which expires in June 2020. The market exclusivity period, which prevents the FDA from approving Actavis’ version, expires in February 2013.
Labopharm said it was reviewing the letter to determine what steps to take, though under the Hatch-Waxman Act of 1984, it is allowed to file a lawsuit against Actavis to prevent the latter from marketing its generic version of the drug.